Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

November 30, 2024

Study Completion Date

August 31, 2025

Conditions
Merkel Cell Carcinoma
Interventions
DRUG

KRT-232

KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

DRUG

Avelumab

Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.

Trial Locations (51)

10021

RECRUITING

Memorial Sloan-Kettering Cancer Center, New York

10029

RECRUITING

Mount Sinai Hospital, New York

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

22031

RECRUITING

Inova Health Care Services, Fairfax

33176

RECRUITING

Miami Cancer Institute, Miami

33612

RECRUITING

Moffitt, Tampa

40202

RECRUITING

Norton Healthcare, Louisville

48109

RECRUITING

University of Michigan, Ann Arbor

60612

RECRUITING

Northwestern Memorial Hospital, Chicago

77030

RECRUITING

University of Texas MD Anderson, Houston

80045

RECRUITING

University of Colorado Anschutz Medical Campus, Aurora

02114

RECRUITING

Massachusetts General Hospital, Boston

02215-5418

RECRUITING

Dana-Farber Cancer Institute, Boston

19111-2434

ACTIVE_NOT_RECRUITING

Fox Chase Cancer Center, Philadelphia

Unknown

RECRUITING

Princess Alexandra Hospital Oncology, Woolloongabba

RECRUITING

Centro Catarinense de Pesquisa (CECAP) - Hospital Santa Catarina de Blumenau, Blumenau

RECRUITING

Instituto Nacional do Cancer, Brasília

RECRUITING

Centro Intergado de Oncologia, Curitiba

RECRUITING

Centro de Pesquisa Clinica em Oncologia, Ijuí

RECRUITING

Clinica De Neoplasias Litoral, Itajaí

RECRUITING

Hospital Paulistano, São Paulo

RECRUITING

Princess Margaret Cancer Centre, Toronto

RECRUITING

CHU de Bordeaux- Hopital Saint-Andre, Bordeaux

RECRUITING

AP-HP Universite Paris Saclay, Gif-sur-Yvette

RECRUITING

CHU de Lille, Lille

RECRUITING

CHU Lyon-Sud, Lyon

RECRUITING

CHU Montpellier, Montpellier

RECRUITING

CHU de Nantes, Nantes

RECRUITING

Hôpital Saint Louis - APHP, Paris

RECRUITING

CHU de Tours, Tours

RECRUITING

Vivantes Network for Health Gmb, Neukölln Clinic, Berlin

RECRUITING

Uniklinik Koln, Cologne

RECRUITING

Universitätsklinikum Erlangen, Erlangen

RECRUITING

Universitätsklinikum Essen (AöR), Essen

RECRUITING

Nationales Centrum für Tumorerkrankungen NCT, Heidelberg

RECRUITING

Universitätsklinik Rostock, Rostock

RECRUITING

Universitats-Hautklinik Tubingen, Tübingen

RECRUITING

Institute for Cancer Research and Treatment, Candiolo

RECRUITING

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli

RECRUITING

AUSL della Romagna, Ravenna

RECRUITING

AOUS Le Scotte, Siena

RECRUITING

OSP Civile Maggiore Borgo Trento, Verona

RECRUITING

University Medical Center Groningen, Groningen

RECRUITING

National Cancer Center, Goyang-si

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital Yonsei University Health System, Seoul

RECRUITING

Hospital Duran i Reynals, Barcelona

RECRUITING

Hospital General Universitario Gregorio Marañn (Madrid), Madrid

RECRUITING

Complejo Hospitalario de Navarra, Pamplona

RECRUITING

Fundacio Investigao Hospital General Universitario de Valencia, Valencia

Cedex 5

RECRUITING

Hôpital de la Timone. Aix-Marseille Université, Marseille

Sponsors
All Listed Sponsors
lead

Kartos Therapeutics, Inc.

INDUSTRY

NCT03787602 - Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | Biotech Hunter | Biotech Hunter